AMARANTUS BIOSCIENCE - BUILDING UP THERAPEUTICS ASSETS
July 28 2015 - 1:15AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: AMARANTUS BIOSCIENCE -
BUILDING UP THERAPEUTICS ASSETS
Amarantus has acquired several pre-commercial therapeutic assets in
recent years, and intends to create value by furthering their
development before out-licensing or commercialising them. The firm
recently acquired ESS-W, which can shorten the time needed to treat
severe burns. Eltoprazine aims to reduce involuntary movements
associated with long-term levodopa therapy in Parkinson’s disease.
These candidates provide long-term potential, and drive our $76m
rNPV.
Amarantus BioScience is a San Francisco-based life sciences firm
developing therapeutics in multiple indications. Eltoprazine is in
Phase IIb trials for Parkinson’s disease, levodopa-induced
dyskinesia (PD-LID). The company’ Diagnostics subsidiary targets
unmet need in neurology.
To view our full report, please click here
Click here to view all of Edison
Investment Research’s published reports
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024